Pfizer Inc 2021 AR2
The report highlights Pfizer's achievements in 2021, including reaching an estimated 1.4 billion patients with its medicines and vaccines, and producing 3 billion doses of the Pfizer-BioNTech COVID-19 vaccine. The company grew its revenues to $81.3 billion and increased its R&D investments to $10.5 billion. Pfizer also advanced its ESG strategy, achieving a 7% reduction in Scope 1 and 2 greenhouse gas emissions from a 2019 baseline, a 15% reduction in water withdrawal, and a 13% reduction in hazardous and non-hazardous waste disposed compared to 2020. Additionally, the company increased diversity among its senior leadership, with women representing 41.5% of vice presidents and above globally.
Company: Pfizer Inc
Sector: Health Care
Country: United States
Year: 2021
Type: AR2
Pages: 56
Pfizer Inc
Annual Review
The report highlights Pfizer's achievements in 2021, including reaching an estimated 1.4 billion patients with its medicines and vaccines, and producing 3 billion doses of the Pfizer-BioNTech COVID-19 vaccine. The company grew its revenues to $81.3 billion and increased its R&D investments to $10.5 billion. Pfizer also advanced its ESG strategy, achieving a 7% reduction in Scope 1 and 2 greenhouse gas emissions from a 2019 baseline, a 15% reduction in water withdrawal, and a 13% reduction in hazardous and non-hazardous waste disposed compared to 2020. Additionally, the company increased diversity among its senior leadership, with women representing 41.5% of vice presidents and above globally.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management